Gastrointestinal:In single-day dosing studies in which adverse events were collected for 7 days, nausea (20%) and vomiting (12%) were recorded as adverse events after the 24hour efficacy assessment period. Hepatic:In comparative trials, elevation of AST and ALT ( > 2 times the upper limit ...